Importantly, in the context of both myeloma and B‐cell precursor acute lymphoblastic leukemia (ALL), very low levels of target antigen (CD19 and CD20) expression may not be a barrier to CAR‐T efficacy.6, 7. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.